Clinical Trial Update: Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) [Phase 3]

View source ↗

Summary

Phase 3 trial results for patidegib topical gel 2% aimed at reducing disease burden in Basal cell nevus syndrome have been posted after completion of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Nevus Syndrome

Drugs mentioned

• Patidegib topical gel 2% (patidegib)

Snippet

Sponsor: Sol-Gel Technologies, Ltd. | Conditions: Basal Cell Nevus Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2024-07-03